Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$5.23
$0.14(2.68%)
At close: 4:00 PM EDT
$5.23
$0.14(2.68%)
Day’s Range― - ―
52-Week Range$1.58 - $6.52
Previous Close$5.46
Volume4.86M
Average Volume (3M)1.11M
Market Cap
$869.95M
Enterprise Value$665.37
Total Cash (Recent Filing)$91.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside139.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$5.98M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetAclaris carries effectively minimal debt and meaningful equity capital, giving the company financial flexibility to fund R&D and absorb setbacks without immediate leverage. This conservative capital structure supports durable optionality for partnerships, licensing or strategic investments over the next 2–6 months.
Cash Runway FundedManagement reports $170.6M in cash and marketable securities and believes this resources the company through end-2028. A multi-year runway materially de-risks near-term financing needs, enabling planned Phase 2b starts, IND filings and multiple pivotal readouts without immediate dilution pressure.
High Product-level MarginsAclaris demonstrates strong gross profitability on existing revenue, implying attractive unit economics for commercialized therapies or partnered assets. High gross margins mean scale could rapidly improve profitability as development programs transition to larger trials or potential launches.
Bears Say
Sustained Cash BurnOperating and free cash flow are deeply negative, reflecting ongoing cash burn to fund trials and development. Persistent negative cash generation will necessitate financing or partnerships to sustain the pipeline, creating execution risk and potential future dilution if catalysts are delayed or costs rise.
Sharp Revenue ContractionRevenues have contracted sharply from prior years, reducing internal funding capacity and increasing dependence on R&D milestones and external capital. Continued top-line decline weakens commercial validation and magnifies the funding burden required to advance multiple clinical programs.
Dilution Risk From ATM ShelfThe refreshed at-the-market facility provides on-demand capital but raises the probability of equity issuance. Given ongoing losses and cash burn, use of the ATM would dilute existing shareholders and could compress per-share economics, a structural financing lever that affects long-term shareholder returns.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.58 and its highest was $6.51 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $869.95M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 91 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 147,198,900 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (139.01% Upside)
$12.50 (139.01% Upside)
Blogger Sentiment
Bearish
ACRS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.00%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$12.50
▲(139.01% Upside)
Technical Analysis
Ownership Overview
11.77% Insiders
6.96% Mutual Funds
10.72% Other Institutional Investors
57.23% Public Companies and Individual Investors